galcanezumab在三级医院偏头痛患者中的应用:健康结果

Section 7: Post Congress additions Pub Date : 2022-03-01 DOI:10.1136/ejhpharm-2022-eahp.386

A. Revuelta Amallo, C. Vila Gallego, M. Vara Urruchua, M. Inclan Conde, B. Belio Aguera, M. Alvarez Lavin, M. Alonso Díez, A. Aguirrezábal Arredondo

{"title":"galcanezumab在三级医院偏头痛患者中的应用:健康结果","authors":"A. Revuelta Amallo, C. Vila Gallego, M. Vara Urruchua, M. Inclan Conde, B. Belio Aguera, M. Alvarez Lavin, M. Alonso Díez, A. Aguirrezábal Arredondo","doi":"10.1136/ejhpharm-2022-eahp.386","DOIUrl":null,"url":null,"abstract":"drugs, presence of analgesia abuse, dosage, of start and end of treatment, reason for end of treatment, number of of monthly migraine headache days (MHD) prior to treatment, and number of MHD after 3 months. All the was obtained the record.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"73 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"4CPS-050 Use of galcanezumab in patients with migraine in a tertiary hospital: health results\",\"authors\":\"A. Revuelta Amallo, C. Vila Gallego, M. Vara Urruchua, M. Inclan Conde, B. Belio Aguera, M. Alvarez Lavin, M. Alonso Díez, A. Aguirrezábal Arredondo\",\"doi\":\"10.1136/ejhpharm-2022-eahp.386\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"drugs, presence of analgesia abuse, dosage, of start and end of treatment, reason for end of treatment, number of of monthly migraine headache days (MHD) prior to treatment, and number of MHD after 3 months. All the was obtained the record.\",\"PeriodicalId\":393937,\"journal\":{\"name\":\"Section 7: Post Congress additions\",\"volume\":\"73 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Section 7: Post Congress additions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2022-eahp.386\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section 7: Post Congress additions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2022-eahp.386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

药物，是否存在镇痛药滥用，剂量，治疗开始和结束的时间，治疗结束的原因，治疗前每月偏头痛天数(MHD)，以及3个月后的MHD天数。所有这些都得到了记录。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

4CPS-050 Use of galcanezumab in patients with migraine in a tertiary hospital: health results

drugs, presence of analgesia abuse, dosage, of start and end of treatment, reason for end of treatment, number of of monthly migraine headache days (MHD) prior to treatment, and number of MHD after 3 months. All the was obtained the record.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Section 7: Post Congress additions

自引率

0.00%

发文量